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Cardiovascular disease is common in patients with chronic kidney disease. 
The increased risk of cardiovascular disease seen in this population is 
attributable to both traditional and novel vascular risk factors. Risk of 
sudden cardiac or arrhythmogenic death is greatly exaggerated in chronic 
kidney disease, particularly in patients with end stage renal disease where 
the risk is roughly 20 times that of the general population. The reasons for 
this increased risk are not entirely understood and while atherosclerosis is accelerated in the 
presence of chronic kidney disease, premature myocardial infarction does not solely account 
for the excess risk. Recent work demonstrates that the structure and function of the heart 
starts to alter early in chronic kidney disease, independent of other risk factors. The 
implications of cardiac remodelling and hypertrophy may predispose chronic kidney disease 
patients to heart failure, arrhythmia and myocardial ischaemia. Further research is needed 
to minimise cardiovascular risk associated with structural and functional heart disease 
associated with chronic kidney disease.
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Abstract
Introduction
Chronic kidney disease (CKd) is a signifi cant worldwide 
health problem. The diagnosis of CKd is based on either 
the presence of reduced kidney function, with a glomerular 
fi ltration rate (gfR) of less than 60 ml/min per 1.73m2, or 
by the presence of albuminuria.1 an individual must have 
either, or both, of these two features for three months or 
more before a diagnosis of CKd is made. The prevalence of 
CKd is rising: observational data from the usa suggest that 
the prevalence of CKd stages 1-4 rose from 10% to 13.1% 
over a 10-year period.2 Part of this increase is thought to be 
due to the rising prevalence of diabetes and hypertension, 
two common causes of CKd. however, patients with early 
CKd are more likely to die of cardiovascular disease than 
of progression of their CKd to end stage renal disease 
(esRd).3 moreover, CKd has been recognised as a risk factor 
for cardiovascular disease, independent of other factors 
and is used in the Q Risk calculator, endorsed by the Joint 
british societies for prevention of cardiovascular disease, 
for estimating risk of cardiovascular disease.4 however, it is 
perhaps not surprising that cardiovascular disease is common 
among patients with CKd. a large number of traditional risk 
factors for cardiovascular disease are common to the CKd 
population (Table 1). for example, obesity, dyslipidaemia, 
hypertension, diabetes, smoking and sedentary lifestyles 
are more commonly found in the dialysis population than 
in the general population. The excess cardiovascular risk 
attributable to CKd merits further study.
Key moments in our understanding of CKD-
related cardiovascular disease
The link between early kidney disease and cardiovascular 
disease was recognised as early as three centuries ago 
(figure 1). in 1836 bright found that 22 out of 100 patients 
who had albuminuria had evidence of marked left ventricular 
hypertrophy (lvh) on autopsy.3 With establishment of dialysis 
programmes as a treatment for esRd in the latter half of the 
20th century, it became clear that premature cardiovascular 
disease was associated with longstanding CKd. in 1974, 
belding scribner, one of the pioneers of maintenance 
haemodialysis therapy, described accelerated atherosclerosis 
in haemodialysis patients.5 The scale and epidemiology of 
excess cardiovascular risk in dialysis patients was further 
described in 1998 by foley, who demonstrated that risk 
of cardiovascular disease in dialysis patients aged 35–44 
was similar to individuals in the general population aged 
over 75, without renal impairment, even after adjustment 
for traditional cardiovascular risk factors. more recently, it 
has become clear that excess cardiovascular risk in CKd 
is not limited to those on renal replacement therapy. go 
et al. demonstrated in a large population-based study that 
reduced estimated gfR was associated with increased 
risks of death, cardiovascular events and hospitalisations 
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that were independent of known risk factors, a history of 
cardiovascular disease and the presence of documented 
proteinuria.6 similarly, a recent meta-analysis showed that 
both falling estimated gfR (below 75 ml/min/1.73m2) and 
increasing albumin creatinine ratios were each independently 
associated with increased cardiovascular mortality risk.7 
Cardiovascular disease in CKD – not just 
accelerated atherosclerosis
only a small proportion of the increased cardiovascular risk 
seen in the CKd population is attributable to the accelerated 
development of atherosclerosis fi rst observed by scribner 
and colleagues.5 nevertheless, ischaemic heart disease as 
a result of atherosclerotic disease is a signifi cant problem in 
the CKd population. in addition to this, patients with CKd do 
worse than their counterparts without renal impairment when 
they do suffer a myocardial infarction, or undergo angioplasty 
or cardiac surgery.8 
We now understand that premature atherosclerosis is not 
the only, or even the main, manifestation of cardiovascular 
disease in the CKd population.9 non-atherosclerotic, or non-
ischaemic cardiac disease, is of much greater importance 
in this patient group. Patients with CKd are at a greatly 
increased risk of sudden cardiac death or arrhythmogenic 
death than their non-CKd counterparts. The risk of sudden 
cardiac death is particularly exaggerated in patients 
undergoing haemodialysis, where the risk is approximately 
20 times that of the general population.10 however, there is an 
increased risk of sudden cardiac death with decreasing gfR 
even very early in CKd. This increased risk is present even in 
those without known cardiovascular disease.11 The reasons 
for this increased risk are not completely understood but are 
thought in part to be attributable to changes in structure and 
function of the cardiac muscle. 
in 2013, half of all deaths in prevalent dialysis patients in the 
usa were attributable to a cardiac cause; 37% of all patients 
died from an arrhythmia or cardiac arrest, 6.7% of patients 
died following an acute myocardial infarction, 5.8% died 
from congestive cardiac failure and 0.5% died from another 
cardiac cause.12 evidence from the uK is similarly compelling; 
sudden presumed cardiac deaths are a big problem in the 
haemodialysis patient group.13
The undeniable causal association between CKd and 
cardiovascular risk means that, in effect, many therapies used 
to prevent progression of CKd also prevent cardiovascular 
disease.3 in fact much of the general management of 
CKd also focuses on reduction of cardiovascular risk. for 
example, strategies such as targeting blood pressure control 
and improving glycaemic indices can simultaneously slow 
progression of CKd and reduce cardiovascular risk.14 but 
what causes the increased cardiovascular risk in CKd if we 
cannot attribute it all to ‘traditional’ cardiac risk factors? This 
continues to be an expanding area of research but we now 
understand that a large number of novel cardiovascular risk 
factors outwith the scope of this review, such as fi broblast graft 
factor-23 or markers associated with vascular calcifi cation 
(e.g. osteoprotegerin, matrix-gla protein) are implicated.
Abnormalities in cardiac structure in patients 
with CKD
abnormalities in cardiac structure common to CKd include 
lvh, ventricular dilation and myocardial fi brosis.15 using 
echocardiography at initiation of renal replacement therapy, 
foley showed that the majority of patients had normal 
cardiac function and dimensions, 32% had left ventricular 
dilatation with preserved systolic function and 74% had 
concentric lvh.16,17 The development of these features, as 
well as impaired cardiac function, often in the absence of 
coronary artery disease, is consistent with a cardiomyopathy 
specifi cally related to renal disease; sometimes termed a 
‘uraemic cardiomyopathy’.18 The presence of these features 
is convincingly associated with increased mortality.19 but why 
are these features so bad?
The presence of lvh at dialysis initiation has been shown to 
be associated with signifi cantly increased mortality.15,20 lvh 
is associated with arrhythmia; observational work suggests 
Table 1 Comparison of prevalence of traditional cardiovascular risk factors between general and dialysis populations
Traditional cardiac risk 
factor
Prevalence within general 
England population (%)
Prevalence within general 
US population (%) 
Prevalence within US 
dialysis population (%)
diabetes 5.8 5 54
hypertension 30 23 96
Total cholesterol > 5 mmol/l* 59 26** 35
hdl < 1 mmol/l 4.2 23** 45
obesity 26 22 26
sedentary lifestyle (failing 
to meet national physical 
exercise recommendations)
58*** 67 80
Current smoker 20 15 28
us data adapted from the ChoiCe study64 english data adapted from report Coronary Heart Disease Statistics 201265
*> 5.1 mmol/l in us data
**Prevalence for general us population not on lipid lowering agents
***only assessed in men
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the risk of sudden cardiac death is almost trebled if lvh is 
present at dialysis initiation.15 The exact mechanisms for this 
increased sudden cardiac death risk are not fully understood. 
ventricular hypertrophy can lead to diastolic heart failure, 
or heart failure with preserved ejection fraction.21 myocyte 
demands are higher with greater myocardial mass and if 
capillary blood supply is not able to meet this increased 
demand, this mismatch can lead to sub-endocardial 
ischaemia.22 increased ventricular mass also promotes 
the development of atrial dilation which increases the risk 
of atrial fi brillation and cardio-embolic strokes as well as 
reducing coronary perfusion reserve, which may predispose 
to future ischaemia.3 
in haemodialysis patients, a number of specifi c determinants 
of increased left ventricular mass (lvm) have been 
demonstrated using cardiac magnetic resonance imaging 
(mRi).23 The main factors predisposing to increased lvm 
demonstrated were the traditional factor of blood pressure, 
as well as novel CKd-specifi c factors: the calcium-phosphate 
product and the volume of fl uid removed at dialysis sessions 
(ultrafi ltration volume).23 earlier studies demonstrated that 
the presence of anaemia (often present as a result of renal 
disease) was a big risk factor for lvh;24 however now that the 
majority of advanced renal failure patients are treated with 
erythropoiesis-stimulating agents this is less of an issue. 
lvh is not only a problem for patients with severe CKd. lvm 
has been shown to be increased early in CKd.25 however, 
CKd is often accompanied by other comorbid conditions 
and these conditions (such as obesity) may also promote 
the development of lvh.19 moreover, hypertension, present 
in up to 87% patients with CKd,27 is a major driver in the 
development of lvh. 
it is probably not surprising that regression of lvm is a 
common primary outcome measure in renal clinical trials,27–30 
the logic being that, as lvh is so bad, a reduction in lvm 
should result in improved outcomes for patients with renal 
1836 Bright  
LVH present on autopsies of patients with 
albuminuria 
1974 Scribner 
Accelerated atherosclerosis in haemodialysis 
patients 
1995 Foley  
Echocardiographic study shows majority of 
patients have cardiac abnormality on starting 
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1998 Foley 
HD patients aged 35-44 similar risk of 
cardiovascular disease as average 75+ year 
old 
2004 Go 
Reduced GFR and albuminuria independently 
associated with increased risk of death, 
cardiovascular events and hospitalisations 
2010 CKD Prognosis Consortium 
Increased risk of cardiovascular disease 
associated with GFR or albuminuria is refined 
Figure 1. our developing understanding of 
CKd-related cardiovascular disease 
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disease. This has been borne out in follow up of some clinical 
trials.31 however a recent systematic review of clinical trials 
targeting lvm in CKd and esRd has cast some doubt on 
the fact that reduced lvm necessarily equates with better 
cardiovascular outcomes.31 in fact, there is some evidence 
that extent of myocardial fi brosis is a better predictor of 
outcome than lvm alone.32
Living kidney donation: a model for studying 
cardiovascular risk in CKD
Reduced kidney function, even without CKd, may predispose 
individuals to an increased risk of cardiovascular disease. 
study of patients who undergo live kidney donation to help 
others with end stage renal disease provides unique insights 
into the effect of a fi xed reduction of renal function on 
cardiovascular health. historically it had been thought that 
while live kidney donation led to an increase in incidence 
of hypertension and a very small, but defi nite, risk of renal 
disease, it was not otherwise associated with reduction 
in lifespan. The reasons for this are complex but include 
the fact that kidney donors are likely to be motivated and 
health-aware in addition to undergoing extra health screening 
as part of the donation process. additionally, there may be 
a psychological benefi t associated with the altruism that 
kidney donation entails. however, a recent controversial 
registry study from norway has demonstrated that live 
kidney donors were at increased risk of cardiovascular 
death compared to matched individuals from the general 
population.33 a mechanistic study using cardiac mRi to 
measure lvm showed that when healthy individuals who 
had donated a kidney were compared with a matched group 
of potential donors who did not proceed to kidney donation, 
there was a signifi cant increase in mRi-determined lvm in 
the group who had undergone a nephrectomy compared 
to the controls. This was despite these ‘healthy’ donors 
still having normal estimated gfR.34 Whether this modest 
increase in lvm translates to an increased risk of cardiac 
disease in this particular patient group remains to be seen.
Cardiac tissue abnormalities in CKD
histological animal studies have demonstrated that as 
lvm increases, tissue abnormalities in keeping with 
myocardial fi brosis may increase in parallel.22 There is also 
considerable evidence that the extent of myocardial fi brosis 
is a stronger predictor of outcome in CKd than lvh alone. in 
a Japanese myocardial biopsy study, the degree of fi brosis 
was highly predictive of arrhythmic death in a haemodialysis 
population.32 it is thought that this diffuse myocardial fi brosis 
may act as an arrhythmia substrate and this may predispose 
to sudden cardiac death. 
mRi has emerged as the leading imaging modality for 
characterising myocardial tissue in CKd. initially gadolinium 
contrast agents were used, with a late diffuse myocardial 
contrast enhancement picture considered a surrogate 
marker of myocardial fi brosis.35 however, gadolinium contrast 
agents have fallen out of favour in the renal community 
because of their association with the rare, but serious, 
condition nephrogenic systemic fi brosis.36 Within the last 
couple of years there has been a move to try and quantify 
myocardial fi brosis using novel non-contrast techniques such 
as T1. in other disease populations, increased T1 times 
have been demonstrated to be representative of myocardial 
fi brosis proven by biopsy. T1 time shows some early promise 
as a potential tool to quantify myocardial fi brosis in the 
renal population. myocardial T1 times have been shown 
to be higher in early CKd than in hypertensive controls 
and healthy volunteers.25 in the haemodialysis population, 
T1 times have also been shown to be prolonged and to 
correlate with lvm.37,38 in the future T1 time may be used as 
a primary endpoint in renal clinical trials aiming to reduce 
cardiovascular risk, but at the moment its clinical utility 
is limited by variability in T1 times across different mRi 
scanners.39
What can we do to reduce cardiovascular 
risk in CKD?
in appropriately selected individuals requiring dialysis, 
restoration of kidney function with kidney transplantation 
is the single intervention associated with most dramatic 
reduction in cardiovascular risk. The effect cannot be tested 
in a randomised trial, but it should be emphasised that 
renal transplantation not only improves quality of life, but is 
associated with a much lower risk of cardiovascular disease 
than remaining on dialysis.40 
in patients with CKd not requiring dialysis, the evidence 
to date suggests that tight control of conventional 
cardiovascular risk factors by controlling blood pressure, 
lipids, smoking cessation and maintenance of heathy lifestyle 
is likely to be benefi cial for reduction of cardiovascular risk, 
although the strength of the supporting evidence is variable. 
once patients are established on dialysis, the evidence for 
interventions to minimise cardiovascular risk are limited, 
outwith ensuring patients are treated broadly along the lines 
of national standards for care of patients needing dialysis.41 
Lipids and CKD
While not strictly a change within the heart, lipid disorders 
are well established as a cardiovascular disease risk factor in 
the general population and so it is logical that priority should 
also be given to understanding and managing lipid disorders 
in CKd. in the general population, a signifi cant reduction in 
cardiovascular risk is achieved with aggressive treatment 
of lipid disorders; this is accepted as standard care and is 
well evidenced.42 Within the last ten years, results of large 
randomised trials examining the effects of lipid-lowering 
therapies in the CKd population have started to emerge. 
The shaRP (study of heart and Renal Protection) study 
demonstrated that lipid lowering therapy is associated with 
lower rates of major atherosclerotic events in patients with 
CKd not requiring dialysis.43 once patients are established 
on dialysis, clinical trials have not demonstrated benefi ts in 
lipid lowering with statins for prevention of cardiovascular 
disease.44,45 This is refl ected in current guidelines which do 
not recommend de novo commencement of lipid lowering 
therapy in dialysis patients to reduce cardiovascular risk.46
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What does the future hold for tackling heart 
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outwith treatment of conventional cardiovascular risk factors, 
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experience a high treatment burden. 
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